EA202191739A1 - ANALOGUES OF RIFAMYCIN AND ANTIBODY-DRUG CONJUGATES WITH THEM - Google Patents

ANALOGUES OF RIFAMYCIN AND ANTIBODY-DRUG CONJUGATES WITH THEM

Info

Publication number
EA202191739A1
EA202191739A1 EA202191739A EA202191739A EA202191739A1 EA 202191739 A1 EA202191739 A1 EA 202191739A1 EA 202191739 A EA202191739 A EA 202191739A EA 202191739 A EA202191739 A EA 202191739A EA 202191739 A1 EA202191739 A1 EA 202191739A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rifamycin
antibody
drug conjugates
analogues
growth
Prior art date
Application number
EA202191739A
Other languages
Russian (ru)
Inventor
Томас Ниттоли
Сынён Шон Чой
Мринмой Саха
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2019/067914 external-priority patent/WO2020132483A1/en
Publication of EA202191739A1 publication Critical patent/EA202191739A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к соединениям-аналогам рифамицина, их промежуточным соединениям и прекурсорам, фармацевтическим композициям, способным к ингибированию роста бактерий (например, роста S. aureus), и лечению бактериальных инфекций (например, инфекций S. aureus). Изобретение дополнительно относится к конъюгатам антитело-лекарственное средство с соединениями-аналогами рифамицина и антителами, например с антителами, специфичными в отношении связанных с инфекционными заболеваниями мишеней, таких как рецептор мембранного гликопротеина (MSR1), тейхоевые кислоты стенки (WTA) или белок A, и способам их применения для ингибирования бактериального роста и лечения бактериальных инфекций.The invention relates to analog compounds of rifamycin, their intermediates and precursors, pharmaceutical compositions capable of inhibiting bacterial growth (for example, the growth of S. aureus), and the treatment of bacterial infections (for example, S. aureus infections). The invention further relates to antibody-drug conjugates with rifamycin analog compounds and antibodies, for example antibodies specific for targets associated with infectious diseases, such as membrane glycoprotein receptor (MSR1), wall teichoic acid (WTA) or protein A, and methods of their use for inhibiting bacterial growth and treating bacterial infections.

EA202191739A 2019-05-08 2019-12-20 ANALOGUES OF RIFAMYCIN AND ANTIBODY-DRUG CONJUGATES WITH THEM EA202191739A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962844860P 2019-05-08 2019-05-08
PCT/US2019/067914 WO2020132483A1 (en) 2018-12-21 2019-12-20 Rifamycin analogs and antibody-drug conjugates thereof

Publications (1)

Publication Number Publication Date
EA202191739A1 true EA202191739A1 (en) 2021-10-13

Family

ID=78572583

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191739A EA202191739A1 (en) 2019-05-08 2019-12-20 ANALOGUES OF RIFAMYCIN AND ANTIBODY-DRUG CONJUGATES WITH THEM

Country Status (1)

Country Link
EA (1) EA202191739A1 (en)

Similar Documents

Publication Publication Date Title
MX2021007524A (en) Rifamycin analogs and antibody-drug conjugates thereof.
WO2020083971A3 (en) New anthelmintic compounds
MX2022000453A (en) Compounds useful to treat influenza virus infections.
WO2018208987A3 (en) Antibacterial compounds
MX2021003084A (en) Antibacterial compounds.
WO2018155813A3 (en) Novel antibacterial protein efal-2 having bacteriolytic ability with respect to enterococcus faecium
EA202090448A1 (en) Dihydrooxadiazinones
RU2011130278A (en) NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF GRAM-POSITIVE INFECTIONS
WO2011140114A3 (en) Anti-glucosaminidase passive immunization for staphylococcus aureus infections
MX2020012030A (en) Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2021010217A (en) Condensed bicyclic heterocyclic derivatives as pest control agents.
CO2021014694A2 (en) A subunit vaccine for the treatment or prevention of a respiratory tract infection
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202190588A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202091118A1 (en) ANTIBACTERIAL COMPOUNDS
WO2019032936A8 (en) Lincosamide antibiotics and uses thereof
MX2021005421A (en) C11-cyclic substituted 13-membered macrolides and uses thereof.
MX2021005423A (en) C10-alkylene substituted 13-membered macrolides and uses thereof.
PE20210123A1 (en) METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE OF THE SAME
EA202191739A1 (en) ANALOGUES OF RIFAMYCIN AND ANTIBODY-DRUG CONJUGATES WITH THEM
EA201992370A1 (en) COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
MX2022008901A (en) Protein-antiviral compound conjugates.
RU2016131195A (en) A method for the treatment of infectious diseases using a composition comprising a plasma-derived immunoglobulin M (IgM)
EA202190316A1 (en) CONDENSED LACTAM DERIVATIVE